Monday, July 23, 2018

2 results for 'ngr-htnf'

MolMed reports top line results of NGR-hTNF in the phase III

By Molmed, published on May 6, 2014

MolMed S.p.A. (MLM.MI) today announced the results of the double-blinded, placebo-controlled Phase III trial of NGR-hTNF versus best investigator choice in 400 patients with malignant pleural mesothelioma who had previously failed a first-line chemotherapy.

Despite not meeting its primary endpoint of improving overall survival (OS) in the entire population, the study showed a statistically significant (unstratified p=0.02; stratified p=0.01) 40% improvement of OS in patients with poorer prognosis who had progressed during or shortly after first-line chemotherapy. These patients represent... (more)

Tags: molmed, ngr-htnf, malignant pleural mesothelioma

MolMed a new patent on its anticancer NGR-hTNF

By Molmed, published on Sep 14, 2013

MolMed S.p.A. (MLM.MI) announces today receipt of the official notification from the European Patent Office of the decision to grant a patent covering the therapeutic use of its investigational anticancer drug NGR-hTNF at low doses. The grant will take effect on the 2nd of October 2013, when it will be published in the European Patent Bulletin.

The administration of NGR-hTNF at low doses is being investigated in a vast clinical program, including a Phase III trial in malignant pleural mesothelioma and several Phase II trials in colorectal, lung, liver and ovarian cancer, and... (more)

Tags: molmed, ngr-htnf, ngr-htnf patent office

« previous next »